Hai Zheng Pharmaceuticals: Signed Exclusive Licensing and Cooperation Agreement for TISA-818

Blue Whale News, July 3rd--Hai Zheng Pharmaceutical announced that the company has signed an exclusive licensing and cooperation agreement with Aitia, introducing Class 1 innovative drug TISA-818 systemic drug formulation rights for development, registration, production, and commercialization in mainland China, Hong Kong, and Macau. The initial payment is 45 million yuan, with development milestone payments totaling up to 100 million yuan, and sales milestone rewards totaling up to 200 million yuan.